You are here: Industry Insights > Alkahest

News List

Grifols to Acquire Alkahest for $146M contractpharma
September 18, 2020
Enhances discovery research and development to identify therapies for age-related diseases.
Grifols to acquire biotech company Alkahest for $146m pharmaceutical-technology
September 17, 2020
Spanish plasma therapies developer Grifols has signed an agreement to acquire the remaining stake in US-based biotechnology firm Alkahest for $146m.
Alkahest Presents Alzheimer’s Disease Study Data americanpharmaceuticalreview
December 16, 2019
Alkahest presented data from its phase 2a study, AKST6019-201, in mild-to-moderate Alzheimer’s Disease (AD).
Alkahest Appoints Chief Business Officer contractpharma
July 25, 2019
Robert Klein, Ph.D. joins the company from Complete Genomics; Served as chief business officer.
Alkahest Doses First Subject in Phase 2 GRF6021 Trial americanpharmaceuticalreview
December 05, 2018
Alkahest announced dosing of the first subject in a Phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson's disease with associated mild cognitive impairment or dementia....
Alkahest Announces Start of Two Phase 2 Clinical Trials of ALK4290 americanpharmaceuticalreview
May 18, 2018
Alkahest announced the initiation of two Phase 2 clinical trials of ALK4290 in patients with the wet form of age-related macular degeneration (AMD).